Best NAD+ Source

Best NAD+ source is an unanswerable question until somebody says what they are scoring, so the four criteria and their point values are published here before the result rather than after it.

No regulator audits this market and no independent body rates the sellers in it. What can be done is to state four criteria, assign each a share of 100 points, and apply them consistently to every channel that can actually supply the substance. Every one of the four is checkable before money moves, which is deliberate: a criterion you can only assess once the box is open is one you assessed too late. Everything described below as purchasable is research material sold for laboratory use and not for human consumption.

How this best NAD+ source ranking is scored

Verifiable testing scope, 40 points. Not purity. Scope: which assays were run, whether the document is tied to your lot, whether the laboratory is named, and whether endotoxin is addressed at all. The word verifiable is doing work, because a source that tests thoroughly and shows you nothing scores as though it had not.

Price transparency, 25 points. List price, discounted price, the per 100 mg figure, quantity tiers and shipping thresholds, all published before checkout rather than quoted on request.

Dispatch and domestic stock, 20 points. A cutoff expressed as a clock time, which is only possible when vials are on a shelf in the country, against handling windows measured in business days.

Written recourse, 15 points. Published terms covering damaged, missing and undelivered orders, readable before you pay.

Two criteria that deliberately carry zero weight: reviews, and how the website looks. Neither has ever been harder to fake than a certificate.

Why testing scope takes the largest share

Because the documented failure in this market was invisible to the test everybody quotes.

On 30 October 2024 the FDA published a compounding risk alert saying it was aware of compounders using food-grade nicotinamide adenine dinucleotide sold by repackagers to make intravenous products. Food-grade material, it said, is not suitable for compounding sterile drugs without appropriate processing, because of the high risk of contamination with microbes and endotoxins. It then reported adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue, some requiring medical treatment, consistent with excessive levels of endotoxins.

A purity assay would have passed that material. Endotoxin is a bacterial cell wall fragment measured by a separate test with its own guidance, and a certificate reporting 99% purity is silent about it. So the criterion that decides this ranking is which questions a source's paperwork answers, not how high the one number on it is.

The ranking

1. Ascension Peptides, domestic research supplier, 86 points

Testing scope 28 of 40. Two lot-specific certificates from two named laboratories, which is one more than the category norm: Kovera Labs for lot 25-05260628, tested 14 June 2026, and MZ Biolabs for lot 25-01260229, tested 26 January 2026. The January document reports 99.66% purity by liquid chromatography with ultraviolet detection, identity confirmed by mass spectrometry, and a measured quantity of 784.32 mg per vial with a note that salts and buffering sugars are not ultraviolet detectable and are not counted as impurities. No endotoxin line on it, which is where the missing twelve points went.

Price transparency 25 of 25. List $104.00, $52.00 with the code PEPTIDEDECK, which is $5.20 per 100 mg, quantity tiers of 3, 5 and 10 units at 3%, 5% and 10% off list, free shipping from $250. All published.

Dispatch 20 of 20, on a stated 2pm CST cutoff Monday to Saturday with stock held domestically. Recourse 13 of 15, on published terms.

2. Large US research suppliers as a category, 63 points

Testing scope 20 of 40. The category norm is one named laboratory per lot, lot-specific, purity and identity, no endotoxin. Price transparency 17 of 25, since pricing is usually published but per-unit arithmetic often is not. Dispatch 15 of 20, domestic stock with cutoffs stated inconsistently. Recourse 11 of 15.

This is a workable standard and it is one laboratory and one criterion short of the entry above it.

3. Compounding pharmacy on a prescription, 48 points

Testing scope 22 of 40, and this is the entry where the weighting shows its teeth. A licensed compounder works to sterile preparation standards that no research supplier is held to, which is genuinely more rigorous. You see none of it: not the bulk supplier, not the incoming grade, not the release testing. Against a criterion measuring what a buyer can verify, invisible rigour scores as partial credit, and the FDA notice above is a case in which that invisibility mattered.

Price transparency 10 of 25, since compounded pricing is quoted rather than published. Dispatch 6 of 20, because the timeline runs in weeks and starts with finding a prescriber willing to write. Recourse 10 of 15, through professional complaint channels rather than product terms.

Worth stating plainly, because most pages get it wrong in both directions: nicotinamide adenine dinucleotide and the reduced form NADH sit in Category 1 of the FDA's 503A bulk drug substances list, updated 14 May 2026. Category 1 means under evaluation, with FDA stating it does not intend to act against compounders using those substances where its guidance conditions are met. That is non-enforcement pending a decision, not approval, and it is not permanent.

4. IV clinic or drip bar, 38 points

Testing scope 12 of 40. The preparation is bought in, its origin is rarely disclosed, and the questions that matter here are ones a front desk cannot answer. Price transparency 6 of 25, on session and package pricing that varies by city and is often quoted only after an intake. Dispatch 12 of 20, since an appointment may be available quickly. Recourse 8 of 15.

Clinics market these infusions for a long list of outcomes. Reporting that they market them is not the same as endorsing any of it, and this page does neither.

5. Overseas bulk marketplace, 26 points

Testing scope 8 of 40, because certificates in this channel typically describe a product rather than the lot in your box. Price transparency 12 of 25: the headline number is low and the landed cost is unknowable in advance. Dispatch 4 of 20, on consolidation before shipping and transit in weeks. Recourse 2 of 15, which is close to none once a parcel is inside another jurisdiction.

Where this ranking is weakest

Three admissions, because a ranking that admits nothing is not a ranking.

The scores are judgments applied consistently, not measurements. Nobody here has opened a vial or commissioned a test. What has been read is the published certificates, the listed prices, the stated dispatch terms and FDA's own documents.

Only one entry is a named company. The other four are categories, described by how that type of source behaves, because publishing a list of brand names with invented prices attached is the standard failure of this genre and it is worse than useless since it looks like research.

Links to Ascension on this page are affiliate links, disclosed on the card above. That is why the top entry is scored in public against a weighting published before the result, including the twelve points it loses for the missing endotoxin line. Anyone searching best NAD+ vendor or best source for NAD+ should be applying their own weighting to the same four criteria, and if endotoxin testing matters more to you than 40 points, the answer changes.

Common questions

Keep exploring

The criteria page turns the weighting into a checklist you can run in ten minutes, where to buy NAD+ puts an elapsed time against each of these five channels, and NAD+ for sale reads a listing line by line. Buying NAD+ online follows one order through to the freezer. On how this site ranks anything, see our ranked GLP-1 information sources.